Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KVD001 in Diabetic Macular Edema
NCT02193113Phase 1Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KVD001 in diabetic macular edema (DME) (3 arms), sponsored by KalVista Pharmaceuticals. Primary endpoint: Number of participants with Adverse Events at 56 days. Started Jul 2014; status: completed.
02
Drugs
KVD001
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02193113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193113.